Abstract: An important barrier to commercialization of pattern recognition myoelectric control of prostheses is the lack of robustness to confounding factors such as electrode shift, skin impedance ...

Regulators in the US and Europe have started to review Novartis' biosimilar version of Biogen's big-selling multiple sclerosis therapy Tysabri, which could reach the market next year. If approved, the ...